Search results
Results from the WOW.Com Content Network
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [ 1 ] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes COVID-19, was isolated in late 2019. [ 1] Its genetic sequence was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten the development of a preventive COVID-19 vaccine. [ 2][ 3][ 4] Since 2020, vaccine ...
AstraZeneca’s COVID-19 vaccine provided strong protection against sickness and eliminated hospitalizations and deaths from the disease across all age groups in a late-stage study in the United ...
JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).
In a late-stage trial, the drug demonstrated "statistically significant and clinically meaningful improvement" in both overall survival and slowing the progression of the cancer in patients for ...
For AstraZeneca's PROVENT trial, close to 5,200 participants without an infection were randomly split into two groups, with one volunteer receiving an ineffective placebo without knowing for every ...
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [ 2][ 3][ 4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [ 5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
The larger trial, among the studies which AstraZeneca submitted to the U.K., showed efficacy of 60 percent and in late December was swiftly granted emergency use approval. Following suit, the ...